JP5980236B2 - ジアミノピリミジン誘導体及びその製造方法 - Google Patents

ジアミノピリミジン誘導体及びその製造方法 Download PDF

Info

Publication number
JP5980236B2
JP5980236B2 JP2013555368A JP2013555368A JP5980236B2 JP 5980236 B2 JP5980236 B2 JP 5980236B2 JP 2013555368 A JP2013555368 A JP 2013555368A JP 2013555368 A JP2013555368 A JP 2013555368A JP 5980236 B2 JP5980236 B2 JP 5980236B2
Authority
JP
Japan
Prior art keywords
propylpyrimidin
group
piperidin
amine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013555368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506591A (ja
Inventor
イ,ヒョンジュ
キム,ドンフン
キム,テギュン
ユン,ヨンエ
シム,ジェヨン
チャ,ミョンフン
ジュン,ウンジョン
アン,キョンギュ
リ,タイウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of JP2014506591A publication Critical patent/JP2014506591A/ja
Application granted granted Critical
Publication of JP5980236B2 publication Critical patent/JP5980236B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013555368A 2011-02-25 2012-02-24 ジアミノピリミジン誘導体及びその製造方法 Active JP5980236B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20110016981 2011-02-25
KR10-2011-0016981 2011-02-25
PCT/KR2012/001423 WO2012115478A2 (en) 2011-02-25 2012-02-24 Diaminopyrimidine derivatives and processes for the preparation thereof

Publications (2)

Publication Number Publication Date
JP2014506591A JP2014506591A (ja) 2014-03-17
JP5980236B2 true JP5980236B2 (ja) 2016-08-31

Family

ID=46721361

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013555368A Active JP5980236B2 (ja) 2011-02-25 2012-02-24 ジアミノピリミジン誘導体及びその製造方法
JP2013555369A Active JP5890436B2 (ja) 2011-02-25 2012-02-24 ジアミノピリミジン誘導体及びその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013555369A Active JP5890436B2 (ja) 2011-02-25 2012-02-24 ジアミノピリミジン誘導体及びその製造方法

Country Status (17)

Country Link
US (4) US9890138B2 (enExample)
EP (2) EP2678331B1 (enExample)
JP (2) JP5980236B2 (enExample)
KR (2) KR101671348B1 (enExample)
CN (2) CN103391935B (enExample)
AU (2) AU2012221927B2 (enExample)
BR (2) BR112013020641B1 (enExample)
CA (2) CA2827072C (enExample)
DK (1) DK2678332T3 (enExample)
ES (2) ES2579830T3 (enExample)
HU (1) HUE029988T2 (enExample)
IN (1) IN2013MN01519A (enExample)
MX (2) MX337477B (enExample)
PL (2) PL2678332T3 (enExample)
PT (1) PT2678332T (enExample)
RU (1) RU2587493C2 (enExample)
WO (2) WO2012115480A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2678332T3 (pl) * 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania
EP2922828B1 (en) 2012-11-21 2020-07-08 PTC Therapeutics, Inc. 4,6-diamino-pyrimidine derivatives as bmi-1 inhibitors for treating cancer
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
TWI692477B (zh) * 2013-08-30 2020-05-01 美商Ptc治療公司 經取代嘧啶bmi-1抑制劑
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN104003944B (zh) * 2014-05-29 2016-08-24 西北师范大学 一种嘧菌胺的制备方法
HRP20250213T1 (hr) 2014-10-13 2025-04-25 Yuhan Corporation Spojevi i pripravci za modulaciju aktivnosti egfr mutantne kinaze
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN105646321A (zh) * 2016-01-07 2016-06-08 中国药科大学 (s)-3-羟基吡咯烷盐酸盐的制备方法
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
KR102441327B1 (ko) * 2018-05-18 2022-09-07 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법
US12023335B2 (en) 2018-08-17 2024-07-02 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
CA3122182A1 (en) * 2018-12-18 2020-06-25 Astrazeneca Ab Pharmaceutical process and intermediates
CN110317176A (zh) * 2019-07-04 2019-10-11 沈阳药科大学 2-氨基嘧啶类化合物及其用途
KR20220006776A (ko) * 2020-07-09 2022-01-18 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법
WO2025104079A1 (en) * 2023-11-17 2025-05-22 Helmholtz-Zentrum für Infektionsforschung GmbH Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4870074A (en) 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
GB9005014D0 (en) 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
NZ274978A (en) * 1993-10-12 1998-04-27 Du Pont Merck Pharma 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
IL112024A (en) * 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
JP2896532B2 (ja) * 1994-08-13 1999-05-31 ユーハン コーポレーション 新規なピリミジン誘導体およびその製造方法
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
IN188411B (enExample) * 1997-03-27 2002-09-21 Yuhan Corp
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
WO2005011758A2 (en) * 2003-07-25 2005-02-10 Ciba Specialty Chemicals Holding Inc. Use of substituted 2,4-bis (alkylamino) pyrimidines or -quinazolines as antimicrobials
JP2007507425A (ja) * 2003-08-29 2007-03-29 ダイノゲン ファーマシューティカルズ,インコーポレイテッド 胃腸管運動障害を処置するために有用な組成物
US20060057972A1 (en) 2004-09-14 2006-03-16 Wikel Harold L Adapter for a modular wireless communication device
US20060128726A1 (en) 2004-11-24 2006-06-15 Xuebao Wang Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
ES2523459T3 (es) 2005-02-25 2014-11-26 Raqualia Pharma Inc Derivados de benzisoxazol
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007062417A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Methods of preparing 2-imidazol-1-yl-4-methyl-6-pyrrolidin-2-yl-pyrimidine and 4-(1-alkylpyrrolidin-2-yl)-2-(1h-imidazol-1-yl)-6-methylpyrimidine derivatives
WO2007114323A1 (ja) * 2006-04-04 2007-10-11 Taisho Pharmaceutical Co., Ltd. アミノピロリジン化合物
CA2648170A1 (en) 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
CN101952275B (zh) * 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
PL2678332T3 (pl) * 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania

Also Published As

Publication number Publication date
BR112013019942A2 (pt) 2018-08-14
KR20120098484A (ko) 2012-09-05
BR112013020641A2 (pt) 2016-10-18
PL2678331T3 (pl) 2016-12-30
US20180072705A1 (en) 2018-03-15
WO2012115480A3 (en) 2012-10-18
US10227330B2 (en) 2019-03-12
EP2678331A4 (en) 2014-07-30
KR20120098483A (ko) 2012-09-05
HUE029988T2 (en) 2017-04-28
US20130338179A1 (en) 2013-12-19
EP2678331A2 (en) 2014-01-01
CA2827072C (en) 2019-01-08
ES2587304T3 (es) 2016-10-21
BR112013020641B1 (pt) 2021-11-03
JP2014506591A (ja) 2014-03-17
JP5890436B2 (ja) 2016-03-22
EP2678331B1 (en) 2016-04-27
CN103391935A (zh) 2013-11-13
PT2678332T (pt) 2016-08-22
EP2678332A2 (en) 2014-01-01
RU2013142188A (ru) 2015-03-27
EP2678332B1 (en) 2016-05-18
WO2012115478A3 (en) 2012-10-18
US10640490B2 (en) 2020-05-05
HK1188214A1 (zh) 2014-04-25
US20130331377A1 (en) 2013-12-12
CN103402997B (zh) 2015-08-26
MX2013009549A (es) 2013-09-06
US20150274700A2 (en) 2015-10-01
BR112013019942B1 (pt) 2022-01-11
WO2012115478A2 (en) 2012-08-30
AU2012221927B2 (en) 2016-04-28
CA2827030A1 (en) 2012-08-30
AU2012221925B2 (en) 2016-05-05
EP2678332A4 (en) 2014-07-23
MX2013009627A (es) 2014-02-17
MX336155B (es) 2016-01-07
PL2678332T3 (pl) 2016-12-30
CN103402997A (zh) 2013-11-20
MX337477B (es) 2016-03-07
US20180111918A1 (en) 2018-04-26
ES2579830T3 (es) 2016-08-17
WO2012115480A2 (en) 2012-08-30
US9850227B2 (en) 2017-12-26
KR101671341B1 (ko) 2016-11-01
IN2013MN01519A (enExample) 2015-06-12
HK1188215A1 (en) 2014-04-25
DK2678332T3 (en) 2016-08-15
KR101671348B1 (ko) 2016-11-01
CA2827072A1 (en) 2012-08-30
US9890138B2 (en) 2018-02-13
RU2013142187A (ru) 2015-03-27
CA2827030C (en) 2019-01-08
JP2014506592A (ja) 2014-03-17
CN103391935B (zh) 2015-12-23
RU2587493C2 (ru) 2016-06-20

Similar Documents

Publication Publication Date Title
JP5980236B2 (ja) ジアミノピリミジン誘導体及びその製造方法
TWI833773B (zh) 化合物
CN1093858C (zh) 用于治疗、特别是治疗良性前列腺增生的喹啉和喹唑啉化合物
HU230787B1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
WO2004078733A1 (en) Quinazolines useful as modulators of ion channels
CN101272685A (zh) 包含二芳基胺的化合物和组合物以及它们作为c-kit受体调节剂的用途
CN1784391B (zh) 可用作离子通道调控剂的喹唑啉
HK1188214B (en) Diaminopyrimidine derivatives and processes for the preparation thereof
RU2587981C2 (ru) Производные диаминопиримидина и способы их получения
RU2800278C2 (ru) Соединения
HK1218536A1 (zh) 含嘧啶环的二环衍生物及其制备方法
HK1188215B (en) Diaminopyrimidine derivatives and processes for the preparation thereof
JPWO1999055674A1 (ja) 1−[(1−置換−4−ピペリジニル)メチル]−4−ピペリジン誘導体、その製造方法、それを含有する医薬組成物および該化合物の中間体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160726

R150 Certificate of patent or registration of utility model

Ref document number: 5980236

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250